Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Malignant Gliomas
Interventions: Gliolan®, Fluorescence-Guided Surgery; Drug · Procedure
Lead sponsor: Constantinos Hadjipanayis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 17
States / cities: Washington D.C., District of Columbia • Delray Beach, Florida • Atlanta, Georgia + 13 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Gold Nanocrystals; Drug
Lead sponsor: Clene Nanomedicine; Industry
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sunscreening Agents
Interventions: BAY987521; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Glycogen Storage Disease Type III
Interventions: UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker; Biological · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Diarrhea
Interventions: Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more

Conditions: Allergic Conjunctivitis
Interventions: bepotastine besilate, 1.5%, Loteprednol etabonate; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fullerton, California

Conditions: Acute Myeloid Leukemia
Interventions: Compound AC220; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 20
States / cities: San Francisco, California • Chicago, Illinois • Indianapolis, Indiana + 14 more

Conditions: Photoaging, Wrinkle, Skin Laxity
Interventions: Fractional Ablative CO2 Laser, Facial Cleanser, Facial Moisturizer, Sunscreen, Basic Ointment; Procedure · Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Blue Ash, Ohio

Conditions: Healthy
Interventions: Azithromycin 600 mg Tablet, Zithromax® 600 mg Tablet; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions: BVD-523, Nab-paclitaxel, Gemcitabine, Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Enteric Hyperoxaluria
Interventions: SYNB8802v1, Placebo; Drug · Other
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Pasireotide, Octreotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 10
States / cities: Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more

Conditions: Influenza
Interventions: CAIV-T, Liquid; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 18 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Monroe, Wisconsin

Conditions: Healthy
Interventions: vapendavir 132 mg capsule, vapendavir 264 mg tablet, vapendavir 24 mg/mL oral suspension; Drug
Lead sponsor: Aviragen Therapeutics; Industry
Eligibility: 19 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy
Interventions: PF-07976016, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: GRANISETRON EXTENDED RELEASE INJECTION (GERSC); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK706769 & KALETRA; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Venous Thromboembolism
Interventions: dabigatran etexilate, standard of care; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Up to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Tampa, Florida + 6 more

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY987521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Intraocular Melanoma
Interventions: nab-paclitaxel; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Chronic Hepatitis B
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Fountain Valley, California • Hacienda Heights, California • Los Angeles, California + 17 more

Conditions: Cystic Fibrosis, Mucociliary Clearance Defect
Interventions: Baseline (Huff-Cough alone), Oscillatory Positive Expiatory Pressure Device, Whole-Body Vibration Platform, High Frequency Chest Wall Oscillatory Vest; Other · Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: SKL24741, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)

Sun Protection Factor Assay (SPF Assay 207/2016)

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

ETEC Logistics Trial (TREK)

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)

Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation

Azithromycin 600 Mg Tablets, Fasting

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

GSK706769/KALETRA Drug-drug Interaction Study

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

18572 - Sun Protection Factor Assay

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection

Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects